Drug development and clinical trials--the path to an approved cancer drug.
about
The increasing urgency for standards in basic biologic research.Ex vivo tumor culture systems for functional drug testing and therapy response predictionDeveloping safety criteria for introducing new agents into neoadjuvant trialsPharmacogenetics in clinical practice: how far have we come and where are we going?Metastasis as a therapeutic target in prostate cancer: a conceptual framework.Commentary on Hey and KimmelmanBridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.An expanding role for cell biologists in drug discovery and pharmacology.An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumorsRepresentation of probabilistic scientific knowledge.Predictive Value Tools as an Aid in Chemopreventive Agent DevelopmentTargeting developmental pathways in children with cancer: what price success?Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.An appraisal of drug development timelines in the Era of precision oncology.Discontinued drugs in 2011: oncology drugs.Reading between the lines; understanding drug response in the post genomic era.Optimizing drug development in oncology by clinical trial simulation: Why and how?Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Heralding a new paradigm in 3D tumor modeling.Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles.The recurrent architecture of tumour initiation, progression and drug sensitivity.Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.Mechanistic understanding in clinical practice: complementing evidence-based medicine with personalized medicine.The impact of preclinical irreproducibility on drug development.Critical evaluation of challenges and future use of animals in experimentation for biomedical research.The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.A novel lab-on-a-chip platform for spheroid metabolism monitoring.Xenograft as In Vivo Experimental Model.Estimating dose-specific cell division and apoptosis rates from chemo-sensitivity experiments.Discontinued in 2013: oncology drugs.
P2860
Q30487147-49540A6F-6940-4CAE-89FC-C391FECFEF6DQ33827247-F9160661-FC0D-43B4-B194-540A83F3FB92Q33895825-5B8B4D02-797F-416B-A459-6BB0A9F6FF70Q34343365-936261C1-8769-4230-AFBC-B073E12C41AEQ34448162-877AF39C-1874-4A71-9DBA-D2520DA5364AQ35820701-7F1C676C-A315-4202-A07B-3143DB7A832FQ36100853-54153748-4B79-438C-B0A0-F46ABF85F3C9Q36288987-CFD6FE54-F71E-41CE-A9ED-7978C1E6E1EAQ36356498-DB9A31E2-B4CA-4A5D-94C4-6CDA40DBBF29Q36779225-0920A641-A837-4EDA-B2B5-E4D0160B80E4Q36786073-6EBBA885-65E0-468B-B1A5-0C5425950A9EQ36887639-52842F2F-7788-4C8A-AB0B-D419E41765D0Q36905620-246E7928-49BC-4372-966D-18C9F3547982Q37238720-6BAFE0AF-56E1-4F4D-95AC-D60298BF9C2BQ37382760-5E346779-5235-489A-B5DD-39B852BE6C27Q37619700-90FDB713-30A4-4589-81BF-ABD7F55DB723Q38057804-33EB1FE3-74DA-4ADD-A061-5BD29A51761DQ38222600-BE00DD53-2743-410A-AF3E-A1410D686544Q38675644-32ED0F33-DA9E-4D4B-8259-E07E855CE521Q38697445-D1C634DE-716F-4AC8-A9CF-3F9BC287FFE2Q38907580-3934E68A-9D34-4771-9227-8D144EDB0D0AQ38957511-8399E45D-6C66-4DF4-9C70-1C2B785AA052Q39001276-D0FA422A-D295-414A-A26A-C90CDDF2E3F9Q39039006-3DF337AD-C10F-4BEE-A957-F117F146ECAAQ39053663-89B2094E-C56E-4052-B266-1B5EC6E1C77EQ39549908-CB3F7A77-F3E7-46A9-BBDC-7149E8B8670BQ41451956-A33564C5-3357-44B5-9018-05DBE57F8AF4Q46483251-EF28F115-28BD-4EC3-8039-5F9135D9EA40Q47609603-115CFB60-F33D-4EC4-8DB3-51BB878509BCQ47743895-407E6E90-C77D-46CD-AF58-2E15676FC71AQ49544632-FB2F92FC-1A84-4EAE-8022-FD0608366E86Q50091273-F425F035-C384-4B64-A735-7FEE14B9713FQ51261562-7428CF17-43D7-4B17-9B4D-0CD717B1CA99
P2860
Drug development and clinical trials--the path to an approved cancer drug.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug development and clinical trials--the path to an approved cancer drug.
@en
Drug development and clinical trials--the path to an approved cancer drug.
@nl
type
label
Drug development and clinical trials--the path to an approved cancer drug.
@en
Drug development and clinical trials--the path to an approved cancer drug.
@nl
prefLabel
Drug development and clinical trials--the path to an approved cancer drug.
@en
Drug development and clinical trials--the path to an approved cancer drug.
@nl
P2860
P1476
Drug development and clinical trials--the path to an approved cancer drug.
@en
P2093
D Gary Gilliland
Eric H Rubin
P2860
P304
P356
10.1038/NRCLINONC.2012.22
P407
P577
2012-02-28T00:00:00Z